Bavarian Nordic Spon (OTCMKTS:BVNRY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Monday. The firm currently has a $19.00 price target on the stock. Zacks Investment Research’s target price suggests a potential upside of 14.46% from the company’s current price.

According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “

Separately, Maxim Group restated a “buy” rating on shares of Bavarian Nordic Spon in a research note on Saturday, February 25th.

Bavarian Nordic Spon (OTCMKTS:BVNRY) traded down 2.35% on Monday, hitting $16.60. The stock had a trading volume of 400 shares. Bavarian Nordic Spon has a 12-month low of $10.44 and a 12-month high of $17.00. The company has a 50 day moving average of $11.70 and a 200 day moving average of $11.70. The company’s market capitalization is $1.48 billion.

Your IP Address:

Get a free copy of the Zacks research report on Bavarian Nordic Spon (BVNRY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Bavarian Nordic Spon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic Spon and related companies with Analyst Ratings Network's FREE daily email newsletter.